January 24, 2019 / 12:08 PM / 7 months ago

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

Jan 24 (Reuters) - ArQule Inc:

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

* ARQULE INC - ENTERED COLLABORATION WITH ROCHE TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

* ARQULE INC - BASILEA EXPECTS TO START A BIOMARKER-DRIVEN MULTI-COHORT PHASE 1/2 STUDY IN MID-2019.

* ARQULE INC - BASILEA PHARMACEUTICA ENTERED COLLABORATION WITH ROCHE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below